Literature DB >> 26810813

A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity.

Jessica Wojciechowski1,2,3, Michael D Wiese2,3, Susanna M Proudman4,5, David J R Foster1,2,3, Richard N Upton1,2,3.   

Abstract

AIMS: Composite indices for quantifying rheumatoid arthritis (RA) disease activity such as the 28-joint disease activity score (DAS28) are comprised of single parameters ('metrics') in various combinations. Population modelling methods were used to evaluate single metrics for their ability to reflect changes in disease activity with a view to understanding and improving composite indices.
METHODS: A total of 11 single metrics of RA disease activity (tender and swollen joint counts, acute phase reactants and global health, pain and physical function assessments) were obtained from 203 patients with recent onset RA. Participants received combination disease-modifying anti-rheumatic drugs (DMARDs) according to a treat-to-target approach with a pre-defined protocol for treatment intensification. Models describing each metric's magnitude and variability of change from baseline to a single 'treated' state in the population were developed using nonmem(®) . Measures that displayed uniformly large changes between states across the population were ranked higher in terms of discriminatory capacity.
RESULTS: Joint counts demonstrated a greater ability to discriminate changes in RA disease activity than others. Correlations between metrics demonstrated that erythrocyte sedimentation rate (ESR) had limited relationships with others for baseline scores and changes in RA disease activity (r generally < 0.2). However it appeared to be important in describing changes for those individuals where ESR levels were initially elevated.
CONCLUSION: It appears unlikely that a single group of metrics may be suitable to capture disease activity changes across all RA patients and defining the most appropriate metric(s) for individual patients will be an important area of future research.
© 2016 The British Pharmacological Society.

Entities:  

Keywords:  disease activity; disease modifying anti-rheumatic drugs; population modelling; rheumatoid arthritis

Mesh:

Substances:

Year:  2016        PMID: 26810813      PMCID: PMC4876190          DOI: 10.1111/bcp.12891

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

Review 1.  Dashboard systems: implementing pharmacometrics from bench to bedside.

Authors:  Diane R Mould; Richard N Upton; Jessica Wojciechowski
Journal:  AAPS J       Date:  2014-06-20       Impact factor: 4.009

2.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.

Authors:  D M van der Heijde; M A van't Hof; P L van Riel; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

3.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

4.  Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression.

Authors:  A A Stenger; M A Van Leeuwen; P M Houtman; G A Bruyn; F Speerstra; B C Barendsen; E Velthuysen; M H van Rijswijk
Journal:  Br J Rheumatol       Date:  1998-11

5.  Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.

Authors:  Susanna M Proudman; Helen I Keen; Lisa K Stamp; Anita T Y Lee; Fiona Goldblatt; Oliver C Ayres; Maureen Rischmueller; Michael J James; Catherine L Hill; Gillian E Caughey; Leslie G Cleland
Journal:  Semin Arthritis Rheum       Date:  2007-03-27       Impact factor: 5.532

6.  Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).

Authors:  S M M Verstappen; J W G Jacobs; M J van der Veen; A H M Heurkens; Y Schenk; E J ter Borg; A A M Blaauw; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-05-22       Impact factor: 19.103

7.  A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity.

Authors:  Jessica Wojciechowski; Michael D Wiese; Susanna M Proudman; David J R Foster; Richard N Upton
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

8.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

9.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156

10.  Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year.

Authors:  Jonathan Kay; Olga Morgacheva; Susan P Messing; Joel M Kremer; Jeffrey D Greenberg; George W Reed; Ellen M Gravallese; Daniel E Furst
Journal:  Arthritis Res Ther       Date:  2014-02-03       Impact factor: 5.156

View more
  1 in total

1.  A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity.

Authors:  Jessica Wojciechowski; Michael D Wiese; Susanna M Proudman; David J R Foster; Richard N Upton
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.